Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Link opens in a new tab
Search content at The Hebrew University of Jerusalem
Home
Profiles
Research units
Research output
Prizes
Impact of the anticancer drug nt157 on tyrosine kinase signaling networks
Shih Ping Su
, Efrat Flashner-Abramson
, Shoshana Klein
, Mor Gal
, Rachel S. Lee
, Jianmin Wu
,
Alexander Levitzki
, Roger J. Daly
*
*
Corresponding author for this work
Alexander Silberman Institute of Life Sciences
Research output
:
Contribution to journal
›
Article
›
peer-review
14
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Impact of the anticancer drug nt157 on tyrosine kinase signaling networks'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Biochemistry, Genetics and Molecular Biology
Anticancer
100%
Receptor Tyrosine Kinase
100%
Tyrosine Kinase
100%
Signal Transduction
66%
Cancer Cell
66%
P38 Mitogen-Activated Protein Kinases
66%
Drug Therapy
66%
Tyrosine Phosphorylation
33%
Cell Proliferation
33%
Proteasome
33%
Tyrosine
33%
Small Molecule
33%
Insulin Receptor
33%
Antiproliferative Activity
33%
Cellular Signalling Network
33%
Peptide
33%
phosphorylation
33%
Bioinformatics Analysis
33%
Keyphrases
Anticancer Drugs
100%
Signaling Network
100%
Tyrosine Kinase Signaling
100%
NT157
100%
Cancer Cells
25%
Drug Response
25%
Drug Treatment
25%
Tyrosine Phosphorylation
12%
Small Molecules
12%
Phosphorylation
12%
Cancer Types
12%
Src Kinase
12%
Co-treatment
12%
Mechanism of Action
12%
Human Melanoma Cells
12%
Tumor Microenvironment
12%
Proteasomal Degradation
12%
Tyrosine
12%
Receptor Tyrosine Kinase
12%
Phosphorylated Peptides
12%
Insulin Receptor Substrate 1 (IRS1)
12%
Bioinformatics Analysis
12%
P38 Mitogen-activated Protein Kinase (p38 MAPK)
12%
Effective Combination
12%
Cell Signaling Pathways
12%
Combination Treatment
12%
SB203580
12%
MAPK Inhibitors
12%
Synergistic Inhibition
12%
Cell Proliferation Inhibition
12%
Antiproliferative Effect
12%
Src Inhibitors
12%
Cellular Signaling Network
12%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase
100%
Malignant Neoplasm
100%
Anticarcinogen
100%
Pharmacotherapy
66%
Tyrosine
66%
Tumor Microenvironment
33%
STAT3 Protein
33%
Melanoma
33%
Proteasome
33%
Insulin Receptor Substrate 1
33%
SB 203580
33%
Peptide
33%
Chemistry
Antineoplastic Agent
100%
Signal Transduction
100%
Tyrosine
100%
Antiproliferative
33%
Insulin Derivative
33%
phosphorylation
33%
Peptide
33%
Tyrosine Phosphorylation
33%
Melanoma Cell
33%